LENZ Therapeutics (LENZ) Interest & Investment Income (2022 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Interest & Investment Income of $2.6 million for Q1 2026, up 13.82% year-over-year from $2.3 million in Q1 2025, and up 17526.67% quarter-over-quarter from $15000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Interest & Investment Income (2022 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Interest & Investment Income for 5 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 13.82% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $4.8 million (up 2.23% YoY), while the FY2025 annual figure was $46000.0, down 75.79% from the prior year.
- Interest & Investment Income improved to $2.6 million in Q1 2026 per LENZ's latest filing, from $15000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.7 million in Q3 2024 and bottomed at -$724000.0 in Q2 2022.
- Historically, Interest & Investment Income has averaged $661250.0 across 5 years, with a median of $1000.0 in 2023.
- Annual changes were most pronounced in 2024 — Interest & Investment Income tumbled 335.71% — and 2025, when it surged 33285.71%.
- LENZ Therapeutics' Interest & Investment Income stood at $548000.0 in 2022, then surged by 300.36% to $2.2 million in 2023, then sank by 114.9% to -$327000.0 in 2024, then surged by 104.59% to $15000.0 in 2025, then soared by 17526.67% to $2.6 million in 2026.
- Business Quant data shows LENZ's Interest & Investment Income at $2.6 million in Q1 2026, $15000.0 in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.27 Mn |
| Mar 31, 2026 | 2.64 Mn |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | -85,000.00 |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | -327,000.00 |
| Sep 30, 2024 | 2.74 Mn |
| Jun 30, 2024 | -61,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 9,000.00 |
| Jun 30, 2023 | -14,000.00 |
| Dec 31, 2022 | 548,000.00 |
| Sep 30, 2022 | -563,000.00 |
| Jun 30, 2022 | -724,000.00 |
| Mar 31, 2022 | -309,000.00 |